Want to see VRTX full AI Analyst Report?

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

6,742 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VRTX Analyst Ratings

Strong Buy

22 Buy

5 Hold

1 Sell

Based on 28 analysts giving stock ratings to

Vertex

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VRTX Stock 12 Month Forecast

Average Price Target

$560.04

▲(26.94% Upside)

Based on 28 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $560.04 with a high forecast of $641.00 and a low forecast of $350.00. The average price target represents a 26.94% change from the last price of $441.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"349":"$349","642":"$642","422.25":"$422.3","495.5":"$495.5","568.75":"$568.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":641,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$641.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":560.0416666666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$560.04</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":350,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$350.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[349,422.25,495.5,568.75,642],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,498.01,509.0092307692308,520.0084615384616,531.0076923076923,542.006923076923,553.0061538461539,564.0053846153846,575.0046153846154,586.0038461538461,597.003076923077,608.0023076923077,619.0015384615385,630.0007692307693,{"y":641,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,498.01,502.78166666666664,507.55333333333334,512.3249999999999,517.0966666666667,521.8683333333333,526.64,531.4116666666666,536.1833333333333,540.9549999999999,545.7266666666667,550.4983333333333,555.27,{"y":560.0416666666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,498.01,486.62461538461537,475.23923076923074,463.8538461538461,452.46846153846155,441.08307692307693,429.6976923076923,418.3123076923077,406.92692307692306,395.5415384615385,384.15615384615387,372.77076923076925,361.3853846153846,{"y":350,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":452.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":462.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":404.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":425.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":425.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":453.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":472.01,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":486.03,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":447.26,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":423.92,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":438.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":498.01,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$641.00

Average Price Target$560.04

Lowest Price Target$350.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Geoff Meacham

Citi

$585

Buy

32.59%

Upside

Reiterated

07/15/26

Vertex Pharmaceuticals (VRTX) Gets a Buy from Citi

Danielle Brill

Truist Financial

$542→$560

Buy

26.93%

Upside

Reiterated

07/13/26

Vertex Pharmaceuticals price target raised to $560 from $542 at TruistVertex Pharmaceuticals price target raised to $560 from $542 at Truist

Tazeen Ahmad

Bank of America Securities

$598→$600

Buy

35.99%

Upside

Reiterated

07/13/26

Vertex Pharmaceuticals: Buy Rating Reaffirmed as Analyst Lifts Price Target from $598 to $600 on Robust CF Growth and Emerging Nephrology/Endocrinology Upside

Evan Seigerman

BMO Capital

$600

Buy

35.99%

Upside

Reiterated

07/13/26

BMO Capital Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Michael Yee

UBS

$545→$585

Buy

32.59%

Upside

Assigned

07/13/26

Vertex Pharmaceuticals price target raised to $585 from $545 at UBSVertex Pharmaceuticals price target raised to $585 from $545 at UBS

Sadia Rahman

Wells Fargo

$550

Buy

24.66%

Upside

Assigned

07/13/26

Analysts Conflicted on These Healthcare Names: Exelixis (NASDAQ: EXEL) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Naz Rahman

Maxim Group

$575

Buy

30.33%

Upside

Reiterated

07/09/26

Vertex: Buy Rating Reaffirmed as Crinetics Deal Broadens Revenue Base; $575 Price Target Maintained

Akash Tewari

Jefferies

$610

Buy

38.26%

Upside

Reiterated

07/08/26

Analysts Conflicted on These Healthcare Names: Certara (NASDAQ: CERT), Nurix Therapeutics (NASDAQ: NRIX) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Eliana Merle

Barclays

$615

Buy

39.39%

Upside

Reiterated

07/08/26

Vertex Pharmaceuticals (VRTX) Receives a Buy from Barclays

Myles Minter

William Blair

―

Buy

―

Reiterated

07/07/26

Vertex’s $10 Billion Crinetics Acquisition Adds Endocrinology Growth Pillars, Supporting Long-Term Buy Thesis

Andrew Fein

H.C. Wainwright

$641

Buy

45.29%

Upside

Reiterated

07/07/26

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Waters (NYSE: WAT)

Cory Kasimov

Evercore ISI

$535

Buy

21.26%

Upside

Reiterated

07/07/26

Analysts Are Bullish on These Healthcare Stocks: Insmed (INSM), Biogen (BIIB)

Joseph Stringer

Needham

―

Hold

―

Reiterated

07/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: HUTCHMED (NASDAQ: HCM), Axsome Therapeutics (NASDAQ: AXSM) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Brian Abrahams

RBC Capital

$543→$570

Buy

29.19%

Upside

Reiterated

07/07/26

Vertex Pharmaceuticals price target raised to $570 from $543 at RBC CapitalVertex Pharmaceuticals price target raised to $570 from $543 at RBC Capital

Phil Nadeau

TD Cowen

$525

Buy

18.99%

Upside

Reiterated

07/07/26

TD Cowen Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Geoff Meacham

Citi

$585

Buy

32.59%

Upside

Reiterated

07/15/26

Vertex Pharmaceuticals (VRTX) Gets a Buy from Citi

Danielle Brill

Truist Financial

$542→$560

Buy

26.93%

Upside

Reiterated

07/13/26

Vertex Pharmaceuticals price target raised to $560 from $542 at TruistVertex Pharmaceuticals price target raised to $560 from $542 at Truist

Tazeen Ahmad

Bank of America Securities

$598→$600

Buy

35.99%

Upside

Reiterated

07/13/26

Vertex Pharmaceuticals: Buy Rating Reaffirmed as Analyst Lifts Price Target from $598 to $600 on Robust CF Growth and Emerging Nephrology/Endocrinology Upside

Evan Seigerman

BMO Capital

$600

Buy

35.99%

Upside

Reiterated

07/13/26

BMO Capital Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Michael Yee

UBS

$545→$585

Buy

32.59%

Upside

Assigned

07/13/26

Vertex Pharmaceuticals price target raised to $585 from $545 at UBSVertex Pharmaceuticals price target raised to $585 from $545 at UBS

Sadia Rahman

Wells Fargo

$550

Buy

24.66%

Upside

Assigned

07/13/26

Analysts Conflicted on These Healthcare Names: Exelixis (NASDAQ: EXEL) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Naz Rahman

Maxim Group

$575

Buy

30.33%

Upside

Reiterated

07/09/26

Vertex: Buy Rating Reaffirmed as Crinetics Deal Broadens Revenue Base; $575 Price Target Maintained

Akash Tewari

Jefferies

$610

Buy

38.26%

Upside

Reiterated

07/08/26

Analysts Conflicted on These Healthcare Names: Certara (NASDAQ: CERT), Nurix Therapeutics (NASDAQ: NRIX) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Eliana Merle

Barclays

$615

Buy

39.39%

Upside

Reiterated

07/08/26

Vertex Pharmaceuticals (VRTX) Receives a Buy from Barclays

Myles Minter

William Blair

―

Buy

―

Reiterated

07/07/26

Vertex’s $10 Billion Crinetics Acquisition Adds Endocrinology Growth Pillars, Supporting Long-Term Buy Thesis

Andrew Fein

H.C. Wainwright

$641

Buy

45.29%

Upside

Reiterated

07/07/26

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Waters (NYSE: WAT)

Cory Kasimov

Evercore ISI

$535

Buy

21.26%

Upside

Reiterated

07/07/26

Analysts Are Bullish on These Healthcare Stocks: Insmed (INSM), Biogen (BIIB)

Joseph Stringer

Needham

―

Hold

―

Reiterated

07/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: HUTCHMED (NASDAQ: HCM), Axsome Therapeutics (NASDAQ: AXSM) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Brian Abrahams

RBC Capital

$543→$570

Buy

29.19%

Upside

Reiterated

07/07/26

Vertex Pharmaceuticals price target raised to $570 from $543 at RBC CapitalVertex Pharmaceuticals price target raised to $570 from $543 at RBC Capital

Phil Nadeau

TD Cowen

$525

Buy

18.99%

Upside

Reiterated

07/07/26

TD Cowen Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

OCGNOcugen

TARAProtara Therapeutics

MIRMMirum Pharmaceuticals

CSTLCastle Biosciences

PCVXVaxcyte

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

3 Months

Cory KasimovEvercore ISI

Success Rate

20/33 ratings generated profit

Average Return

+3.98%

Copying Cory Kasimov's trades and holding each position for 3 Months would result in 60.61% of your transactions generating a profit, with an average return of +3.98% per trade.

1 Year

Salveen RichterGoldman Sachs

Success Rate

16/21 ratings generated profit

Average Return

+10.65%

Copying Salveen Richter's trades and holding each position for 1 Year would result in 76.19% of your transactions generating a profit, with an average return of +10.65% per trade.

2 Years

Salveen RichterGoldman Sachs

Success Rate

19/21 ratings generated profit

Average Return

+16.42%

Copying Salveen Richter's trades and holding each position for 2 Years would result in 90.48% of your transactions generating a profit, with an average return of +16.42% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRTX Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VRTX has received 46 Buy Ratings, 8 Hold Ratings, and 1 Sell Ratings. VRTX average Analyst price target in the past 3 months is 560.04.

Each month's total comprises the sum of three months' worth of ratings.

VRTX Financial Forecast

VRTX Earnings Forecast

Next quarter’s earnings estimate for VRTX is $4.74 with a range of $3.99 to $5.17. The previous quarter’s EPS was $4.47. VRTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.

VRTX Sales Forecast

Next quarter’s sales forecast for VRTX is $3.23B with a range of $3.13B to $3.31B. The previous quarter’s sales results were $3.01B. VRTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.

VRTX Stock Forecast FAQ

What is VRTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Vertex Pharmaceuticals Inc.’s 12-month average price target is 560.04.

What is VRTX’s upside potential, based on the analysts’ average price target?

Vertex Pharmaceuticals Inc. has 26.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VRTX a Buy, Sell or Hold?

Vertex Pharmaceuticals Inc. has a consensus rating of Strong Buy which is based on 22 buy ratings, 5 hold ratings and 1 sell ratings.

What is Vertex Pharmaceuticals Inc.’s price target?

The average price target for Vertex Pharmaceuticals Inc. is 560.04. This is based on 28 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $641.00 ,the lowest forecast is $350.00. The average price target represents 26.94% Increase from the current price of $441.2.

What do analysts say about Vertex Pharmaceuticals Inc.?

Vertex Pharmaceuticals Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 28 Wall Streets Analysts.

How can I buy shares of VRTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

VRTX Analyst Ratings

VRTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vertex Pharmaceuticals

VRTX Analyst Recommendation Trends

VRTX Financial Forecast

VRTX Earnings Forecast

VRTX Sales Forecast

VRTX Stock Forecast FAQ

Detailed List of Analyst Forecasts